ReviewJournal of controlled release : official journal of the Controlled Release Society2015
Small molecules targeting microRNA for cancer therapy: Promises and obstacles.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 97 citations in OpenAlex.
- microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer.Non-coding RNA · 2026Review
- Emerging Roles of MicroRNAs in Diffuse Large B-Cell Lymphoma: From Molecular Mechanisms to Clinical Translation, Liquid Biopsy, and Precision Medicine.Biomedicines · 2026Review
- Graphene-Based Nanosystem for Targeted Delivery of Anti-Sense miRNA-21 on Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2026Article
- Exploring the therapeutic potential of microRNAs: targeted gene regulation strategies for enhanced cancer therapy.Journal, genetic engineering & biotechnology · 2025Review
- Docking and Molecular Dynamics Simulation-Based Analysis of Advanced Small-Molecule Kinase Inhibitors Identified pre-let-7 miRNA Binders.Chembiochem : a European journal of chemical biology · 2025Article
- Unraveling LncRNAs: the future of lung cancer treatment.Journal of the Egyptian National Cancer Institute · 2025Review
- RNA-based therapies for colorectal cancer: targeting the β-catenin pathway via microbiota -modulated miRNAs.Frontiers in molecular biosciences · 2025Review
- The regulatory role and therapeutic potential of long non-coding RNA in non-small cell lung cancer.Journal of Cancer · 2025Review
- Quercetin and microRNA Interplay in Apoptosis Regulation: A New Therapeutic Strategy for Cancer?Current medicinal chemistry · 2025Review
- MiR-5590-3p inhibits the proliferation and invasion of ovarian cancer cells through mediating the Wnt/β-catenin signaling pathway by targeting TNIK.Histology and histopathology · 2024Article
- microRNA-184 in the landscape of human malignancies: a review to roles and clinical significance.Cell death discovery · 2023Review
- Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges.Military Medical Research · 2023Review
- Regulatory miRNAs, circRNAs and lncRNAs in cell cycle progression of breast cancer.Functional & integrative genomics · 2023Review
- Gentamycin Rationally Repositioned to Inhibit miR-34a Ameliorates Oxidative Injury to PC12 Cells.ACS omega · 2023Article
- Transcriptional Inhibition of MicroRNA miR-122 by Small Molecules Reduces Hepatitis C Virus Replication in Liver Cells.Journal of medicinal chemistry · 2022Article
- Review
- Cytosolic microRNA-inducible nuclear translocation of Cas9 protein for disease-specific genome modification.Nucleic acids research · 2022Article
- Targeting non-coding RNAs to overcome cancer therapy resistance.Signal transduction and targeted therapy · 2022Review
- Fine-tuning miR-21 expression and inhibition of EMT in breast cancer cells using aromatic-neomycin derivatives.Molecular therapy. Nucleic acids · 2022Article
- HT-SELEX-based identification of binding pre-miRNA hairpin-motif for small molecules.Molecular therapy. Nucleic acids · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Aberrant expression of miRNAs is critically implicated in cancer initiation and progression. Therapeutic approaches focused on regulating miRNAs are therefore a promising approach for treating cancer. Antisense oligonucleotides, miRNA sponges, and CRISPR/Cas9 genome editing systems are being investigated as tools for regulating miRNAs. Despite the accruing insights in the use of these tools, delivery concerns have mitigated clinical application of such systems. In contrast, little attention has been given to the potential of small molecules to modulate miRNA expression for cancer therapy. In these years, many researches proved that small molecules targeting cancer-related miRNAs might have greater potential for cancer treatment. Small molecules targeting cancer related miRNAs showed significantly promising results in different cancer models. However, there are still several obstacles hindering the progress and clinical application in this area. This review discusses the development, mechanisms and application of small molecules for modulating oncogenic miRNAs (oncomiRs). Attention has also been given to screening technologies and perspectives aimed to facilitate clinical translation for small molecule-based miRNA therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.